Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LifeCell Corp.

Division of Allergan PLC
www.lifecell.com

Latest From LifeCell Corp.

Medical Aesthetics: Key Players In A Largely Untapped Market

Medical aesthetics is a growing, but largely untapped biopharma niche with unique consumer marketing and doctor relationship-building strategies where key players have honed their skills for many years. Allergan's blockbuster Botox dominates, but competitors are gaining ground.

Aesthetics Business Strategies

Exec Chat: KCI CEO Andrew Eckert Foresees Big Year For Wound-Care Company

Since selling its LifeCell aesthetic and surgical products business to Allergan in early 2017, Acelity has refocused its commercial efforts, and its name, on the KCI wound-care business, with significant investments in medical education, clinical studies and R&D in that sector, as well as the recent acquisition of UK-based Crawford Healthcare.

Exec Chat Innovation

Device/Diagnostics Quarterly Deal-Making Statistics, Q2 2017

Device and diagnostics fundraising slumped in Q2, but there was a substantial uptick in M&A activity. Device financings totaled just slightly over half of the previous quarter, while acquisitions grew almost six-fold, thanks primarily to Becton Dickinson's $23.5 billion play for CR Bard. Financing in diagnostics slid to $1.03 billion, less than half of Q1, whereas the $1.7 billion in M&As (most of that from PerkinElmer's $1.3 billion buy of EuroImmun) was more than double Q1's aggregate.

Medical Device In Vitro Diagnostics

Device/Diagnostics Quarterly Deal-Making Statistics, Q1 2017

Medtech companies brought in $2.3 billion in financing in Q1 2017, a slight decrease from Q4 2016; device M&A deals totaled $5.8 billion, a sharp decline from the prior quarter, but there were some billion-dollar deals. Q1 diagnostics financings – totaling $1.2 billion (thanks to a $900 million Series B round by cancer diagnostics company Grail) – showed a significant increase over the preceding quarter, as did the Q1 M&As at $700 million versus the previous $87 million.

Medical Device In Vitro Diagnostics
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
    • Implantable Devices
    • Surgical Equipment & Devices
  • Therapeutic Areas
  • Dermatology
  • Musculoskeletal & Connective Tissue Disorders
  • Wound Healing & Tissue Repair
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Allergan PLC
  • Senior Management
  • Paul G Thomas, Chmn., Pres. & CEO
    Steven T Sobieski , VP, Fin. & Admin. & CFO
    Bruce Lamb, SVP, Dev. & Regulatory Affairs
    Lisa Colleran, VP, Mktg. & Bus. Dev.
  • Contact Info
  • LifeCell Corp.
    Phone: (800) 367-5737
    1 Millennium Way
    Branchburg, NJ 08876
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register